

**Amendments to the Claims**

Please cancel Claim 13. Please add new Claims 43-75. The Claim Listing below will replace all prior versions of the claims in the application:

**Claim Listing**

- 1-42. (Canceled)
43. (New) A composition comprising a stress protein, or portion thereof, and a melanoma antigen peptide, wherein the composition, when administered to an individual, induces or enhances an immune response against the melanoma antigen peptide.
44. (New) The composition of claim 43, wherein the stress protein is a heat shock protein (hsp).
45. (New) The composition of claim 43, wherein the stress protein is a mycobacterial stress protein.
46. (New) The composition of claim 43, wherein the stress protein is a member of one of the following families of stress proteins: the hsp70 family; the hsp60 family; the groES family; the DnaJ family; the hsp90 family; and the small molecular weight family of stress proteins.
47. (New) The composition of claim 43, wherein the stress protein is an *M. bovis* BCG stress protein.
48. (New) The composition of claim 47, wherein the *M. bovis* BCG stress protein is an *M. bovis* BCG hsp65 protein.
49. (New) The composition of claim 43, wherein the stress protein is fused to the melanoma antigen peptide via a peptide bond.

50. (New) The composition of claim 43, wherein the stress protein is joined to the melanoma antigen peptide via chemical conjugation.
51. (New) The composition of claim 43, wherein the composition comprises a portion of the stress protein.
52. (New) The composition of claim 43, wherein the composition consists of a stress protein, or a portion thereof, and a melanoma antigen peptide.
53. (New) The composition of claim 43, wherein the composition consists of the stress protein, or a portion thereof, the melanoma antigen peptide, and a pharmaceutically acceptable carrier or excipient.
54. (New) A pharmaceutical preparation comprising the composition of claim 43.
55. (New) The pharmaceutical preparation of claim 54, wherein the stress protein is an hsp.
56. (New) The pharmaceutical preparation of claim 54, wherein the stress protein is a mycobacterial stress protein.
57. (New) The pharmaceutical preparation of claim 54, wherein the stress protein is a member of one of the following families of stress proteins: the hsp70 family; the hsp60 family; the groES family; the DnaJ family; the hsp90 family; or the small molecular weight family of stress proteins.
58. (New) The pharmaceutical preparation of claim 54, wherein the stress protein is an *M. bovis* BCG stress protein.
59. (New) The pharmaceutical preparation of claim 58, wherein the *M. bovis* BCG stress

protein is an *M. bovis* BCG hsp65 protein.

60. (New) The pharmaceutical preparation of claim 54, wherein the composition comprises a portion of the stress protein.
61. (New) The pharmaceutical preparation of claim 54, wherein the preparation consists of the stress protein, or a portion thereof, the melanoma antigen peptide, and a pharmaceutically acceptable carrier or excipient.
62. (New) A pharmaceutical preparation comprising the composition of claim 49.
63. (New) The pharmaceutical preparation of claim 62, wherein the preparation consists of the stress protein, or the portion thereof, the melanoma antigen peptide, and a pharmaceutically acceptable carrier or excipient.
64. (New) A pharmaceutical preparation comprising the composition of claim 50.
65. (New) The pharmaceutical preparation of claim 64, wherein the preparation consists of the stress protein, or the portion thereof, the melanoma antigen peptide, and a pharmaceutically acceptable carrier or excipient.
66. (New) An isolated nucleic acid that encodes a fusion protein comprising a stress protein, or a portion thereof, fused via a peptide bond to a melanoma antigen peptide, wherein the fusion protein, when administered to an individual, induces or enhances an immune response against the melanoma antigen peptide.
67. (New) The nucleic acid of claim 66, wherein the stress protein is an hsp.
68. (New) The nucleic acid of claim 66, wherein the stress protein is a mycobacterial stress protein.

69. (New) The nucleic acid of claim 66, wherein the stress protein is a member of one of the following families of stress proteins: the hsp70 family; the hsp60 family; the groES family; the DnaJ family; the hsp90 family; or the small molecular weight family of stress proteins.
70. (New) The nucleic acid of claim 66, wherein the stress protein is an *M. bovis* BCG stress protein.
71. (New) The nucleic acid of claim 70, wherein the *M. bovis* BCG stress protein is an *M. bovis* BCG hsp65 protein.
72. (New) The nucleic acid of claim 66, wherein the fusion protein comprises a portion of the stress protein.
73. (New) The nucleic acid of claim 66, wherein the fusion protein consists of the stress protein, or a portion thereof, and the melanoma antigen peptide.
74. (New) An expression vector comprising the nucleic acid of claim 66.
75. (New) A cell comprising the expression vector of claim 74.